Matthew Forman was a brilliant British scientist whose life’s work has already changed thousands of lives, and whose legacy now aims to change thousands more.

Born in West Sussex in 1971 and later settling in Leicester, Matthew dedicated his life to understanding the most complex problems in science and engineering, and to using that knowledge to help others. 

After achieving a first-class BEng from De Montfort University and completing a PhD in computer science and modelling, Matthew spent several years in academia teaching and engaged in research before moving into industry. It was there, over the last two decades of his life, that he developed pioneering ideas and tools at the forefront of non-invasive prenatal testing (NIPT). 

The tests involved taking a blood test from a pregnant mother and removed the need for amniocentesis.   At the time of his death, he had over a hundred scientific patents and was hoping to extend the technology to test for various forms of cancer.  His work helped reduce the need for invasive procedures such as amniocentesis, improving safety and peace of mind for countless families.  

But Matthew’s contributions extended far beyond science. He was known for his kindness, his patience, and his mentorship. His colleagues saw him as a guiding force; his friends and family saw him as someone who would drop everything to repair a broken radio, computer, or synthesizer simply because he loved to help. At home, he shared 25 wonderful years with his partner, Paul G. Abel, and filled their space with music created on his ever-growing collection of synthesizers. 

A Rare Diagnosis 

In May 2024, Matthew began experiencing severe headaches. A CT scan revealed a pituitary mass initially suspected to be a benign adenoma. But the tumour grew rapidly, causing AVPD (previously known as diabetes insipidus) and memory difficulties. 

A fullbody CT scan, ordered by his endocrinologist Professor Miles Levy at Leicester Royal Infirmary, revealed the devastating truth: a large lung tumour, an aggressive nonsmall cell adenocarcinoma, had spread to Matthew’s pituitary gland. Fewer than 200 such cases have ever been documented. 

Matthew underwent delicate neurosurgery performed by Mr Laurence Glanz at Queen’s Medical Centre in Nottingham, followed by chemotherapy and immunotherapy back at LRI. Despite the exceptional care he received, the treatment was ultimately unsuccessful. Matthew passed away from complications of sepsis in November 2024.